MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted condition including simple steatosis alone or associated with inflammation and ballooning (non-alcoholic steatohepatitis) and eventually fibrosis. The NAFLD incidence has increased over the last twenty years becoming the most frequent chronic liver disease in industrialized countries. Obesity, visceral adiposity, insulin resistance, and many other disorders that characterize metabolic syndrome are the major predisposing risk factors for NAFLD. Furthermore, different factors, including genetic background, epigenetic mechanisms and environmental factors, such as diet and physical exercise, contribute to NAFLD development and progression. Several lines of evidence demonstrate that specific microRNAs expression profiles are strongly associated with several pathological conditions including NAFLD. In NAFLD, microRNA deregulation in response to intrinsic genetic or epigenetic factors or environmental factors contributes to metabolic dysfunction. In this review we focused on microRNAs role both as controlled and controllers molecules in NAFLD development and/or their eventual value as non-invasive biomarkers of disease.
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Nadia
N
Panera
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Daniela
D
Gnani
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Annalisa
A
Crudele
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Sara
S
Ceccarelli
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Valerio
V
Nobili
Nadia Panera, Valerio Nobili, Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.
Anna
A
Alisi
D000818:Animals; D044127:Epigenesis, Genetic; D005786:Gene Expression Regulation; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D006801:Humans; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D010641:Phenotype; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D015398:Signal Transduction
D005819:Genetic Markers; D035683:MicroRNAs
Fibrosis; Liver steatosis; MicroRNAs; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis